Substituted acylanilides and methods of use thereof

Details Substituted acylanilides and methods of use thereof Substituted acylanilides and methods of use thereof

2007-08-24

2011-12-20

Kumar, Shailendra (Department: 1621)

Organic compounds -- part of the class 532-570 series

Organic compounds

Nitriles

C514S522000

Reexamination Certificate

active

08080682

ABSTRACT:
This invention provides SARM compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter alia, a muscle wasting disease and/or disorder or a bone-related disease and/or disorder.

REFERENCES:
patent: 3875229 (1975-04-01), Gold
patent: 4139638 (1979-02-01), Neri et al.
patent: 4191775 (1980-03-01), Glen
patent: 4239776 (1980-12-01), Glen et al.
patent: 4282218 (1981-08-01), Glen et al.
patent: 4386080 (1983-05-01), Crossley et al.
patent: 4465507 (1984-08-01), Konno et al.
patent: 4636505 (1987-01-01), Tucker
patent: 4880839 (1989-11-01), Tucker
patent: 4977288 (1990-12-01), Kassis et al.
patent: 5162504 (1992-11-01), Horoszewicz
patent: 5609849 (1997-03-01), Kung
patent: 5656651 (1997-08-01), Sovak et al.
patent: 6019957 (2000-02-01), Miller et al.
patent: 6071957 (2000-06-01), Miller et al.
patent: 6160011 (2000-12-01), Miller et al.
patent: 6482861 (2002-11-01), Miller et al.
patent: 6492554 (2002-12-01), Dalton et al.
patent: 6569896 (2003-05-01), Dalton et al.
patent: 6838484 (2005-01-01), Steiner et al.
patent: 6998500 (2006-02-01), Dalton et al.
patent: 7026500 (2006-04-01), Dalton et al.
patent: 7705182 (2010-04-01), Dalton et al.
patent: 2001/0012839 (2001-08-01), Miller et al.
patent: 2002/0173495 (2002-11-01), Dalton et al.
patent: 2005/0038110 (2005-02-01), Steiner et al.
patent: 2006/0111441 (2006-05-01), Dalton et al.
patent: 2006/0183931 (2006-08-01), Dalton et al.
patent: 0 040 932 (1981-12-01), None
patent: 0 100 172 (1984-02-01), None
patent: 000 2892 (1985-02-01), None
patent: 0253 503 (1991-12-01), None
patent: 1360001 (1970-03-01), None
patent: 52-128329 (1977-10-01), None
patent: 54-63047 (1980-12-01), None
patent: WO 95/19770 (1995-07-01), None
patent: WO 98 05962 (1998-02-01), None
patent: WO 98/53826 (1998-12-01), None
patent: WO 98/55153 (1998-12-01), None
patent: WO 01 27622 (2001-04-01), None
patent: WO 01 28990 (2001-04-01), None
patent: WO 01 34563 (2001-05-01), None
patent: WO 02 00617 (2002-01-01), None
patent: WO 02/16310 (2002-02-01), None
patent: WO 03 011302 (2003-02-01), None
patent: WO 03/049675 (2003-06-01), None
patent: WO 03/065992 (2003-08-01), None
patent: WO 03/074471 (2003-09-01), None
patent: WO 2004/064747 (2004-08-01), None
patent: WO 2005/037201 (2005-04-01), None
patent: WO 2005/120483 (2005-12-01), None
patent: WO 2007/027582 (2007-03-01), None
Byrn et al. Solid-State Chemistry of Drugs, 2d, Chapter 11 Hydrates and Solvates, 233-247.
Morissette et al. Adv. Drug Delivery Rev. 2004, 56, 275-300.
I A.M. Rouhi, Chem. & Eng. News, Feb. 24, 2003, 81(8), 32-35.
Carter et al., Chemotherapy of Cancer, second edition, John Wiley & Sons, N.Y., N.Y., 1981, pp. 362-365.
Kim, Juhyun et al., “The para substituent of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamides is a major structural determinant of in vivo disposition and activity of selective androgen receptor modulators”, J. of Pharmacology and Experimental Therapeutics, 315(1), 230-239 (2005).
U.S. Appl. No. 09/935,044, filed Aug. 23, 2001, Dalton et al.
U.S. Appl. No. 09/935,045, filed Aug. 23, 2001, Dalton et al.
U.S. Appl. No. 09/644,970, filed Aug. 2, 2000, Dalton et al.
U.S. Appl. No. 10/298,229, filed Nov. 28, 2002, Miller et al.
U.S. Appl. No. 10/270,232, filed Oct. 15, 2002, Dalton et al.
U.S. Appl. No. 10/277,108, filed Oct. 23, 2002, Dalton et al.
U.S. Appl. No. 10/270,233, filed Oct. 15, 2002, Dalton et al.
U.S. Appl. No. 10/270,732, filed Oct. 15, 2002, Dalton et al.
U.S. Appl. No. 10/371,213, filed Feb. 24, 2003, Dalton et al.
U.S. Appl. No. 10/371,209, filed Feb. 24, 2003, Dalton et al.
U.S. Appl. No. 10/371,211, filed Feb. 24, 2003, Dalton et al.
U.S. Appl. No. 10/371,210, filed Feb. 24, 2003, Dalton et al.
U.S. Appl. No. 10/359,270, filed Feb. 6, 2003, Steiner et al.
U.S. Appl. No. 10/310,150, filed Dec. 5, 2002, Steiner et al.
Howard Tucker and Glynne J. Chesterson, J. Med Chem. 1988, 31, pp. 885-887, “Resolution of the Nonsteroidal Antiandrogen—4′-Cyano-3-[(4-fluorophenyl)sulfony1]-2-hydroxy-2-methy1-3′-(trifluoromethyl)-propionanilide and the Determination of the Absolute Configuration of the Active Enantiomer”.
D. McKillop, et al., “Enantioselective metabolism and pharmacokinetics of Casodex in the male rat”, Xenobiotica, 1995, vol. 25, No. 6, 623-634.
Leonid Kirkovsky, et al., “[125I]-Radionated Bicalutamide Analogs as Potential Imaging Agents for Prostate Cancer”, Poster Presentation MEDI 155, 214th ACS National Meeting, Las Vegas, NV, Sep. 7-11, 1997, Department of Pharmaceutical Sciences, University of Tennessee, Memphis, TN 38163.
David T. Baird and Anna F. Glasier, “Hormonal Contraception—Drug Therapy”, The New England Journal of Medicine, May 27, 1993, pp. 1543-1549.
F.C. W. Wu, “Male Contraception: Current Status and Future Prospects”, Clinical Endocrinology, (1988), 29, pp. 443-465.
World Health Organisation Task Force on Methods for the Regulation of Male Fertility, “Contraceptive efficacy of testosterone-induced azoospermia in normal men”, The Lancet, vol. 336, Oct. 20, 1990, pp. 955-959and 1517-1518.
C. G. Francisco, et al., “Long-acting contraceptive agents: testosterone esters of unsaturated acids”, Steroids, Jan. 1990, vol. 55, Butterworths.
John M. Hoberman and Charles E. Yesalis, “The History of Synthetic Testosterone”, Scientific American, Feb. 1995, pp. 76-81.
Leonid Kirkovsky, et al., “Approaches to Irreversible non-steroidal chiral antiandrogens”, Department of Pharmaceutical Sciences, University of Tennessee, 47th Southeast/51st Southwest Joint Regional Meeting of the American Chemical Society, Memphis, TN, Nov. 29-Dec. 1, 1995.
David J. Handelsman, “Bridging the gender gap in contraception: another hurdle cleared” The Medical Journal of Australia, vol. 154, Feb. 18, 1996, pp. 230-233.
Edwards JP, Higuchi RI, Winn DT, Pooley CLF, Caferro TR, Hamann LG, Zhi L, Marschke KB, Goldman ME, and Jones TK. Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano [3, 2-g] quinolin-2-one. Bioorg. Med. Chem. Lett., 9: 1003, 1999.
Zhi L, Tegley CM, Marschke KB, and Jones TK. Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolone. Bioorg. Med. Chem. Lett., 9: 1009, 1999.
Higuchi RI, Edwards JP, Caferro TR, Ringgenberg JD, Kong JW, Hamann LG, Arienti KL, Marschke KB, Davis RL, Farmer LJ, and Jones TK. 4-Alkyl- and 3,4-diakly1-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: potent, nonsteroidal androgen receptor agonists. Bioorg. Med. Chem. Lett., 9:1335, 1999.
Hamann LG, Mani NS, Davis RL, Wang XN, Marschke KB, and Jones TK. Discovery of a potent, orally active nonsteroidal androgen receptor agonist: 4-ethy1-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyridono[5,6-g]-quinoline (LG121071). J. Med. Chem., 42: 210, 1999.
Rosen J, Day A, Jones TK, Jones ET, Nadzan AM, and Stein RB. Intracellular receptors and signal transducers and activators of transcription superfamilies: novel targets for small-molecule drug discovery. J. Med. Chem., 38: 4855, 1995.
Dalton JT, Mukherjee A, Zhu Z, Kirkovsky L, and Miller DD. Discovery of Nonsteroidal Androgens. Biochem. Biophys. Res. Comniun., 244(1):1-4, 1998.
Edwards JP, West SJ, Pooley CLF, Marschke KB, Farmer LJ, and Jones TK. New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2-(1H)-Pyrololidino[3,2-g]quinolone. Bioorg. Med. Chem. Lett., 8: 745, 1998.
Dalton JT, et al “Pharmacokinetics of Aminolevulinic Acid after Oral and Intravenous Dosing in Dogs.” Drug Metabolism and Disposition, 27 (4):432-435, 1999.
Yin D, et al “Key Structural Features of Nonsteroidal Ligands for Binding and Activation of the Androgen Receptor.” Molecular Pharmacology, 63:211-223, 2003.
Eliason et al., “High Throughput Fluorescence Polarization-Based Screening Assays for the Identification of Novel Nuclear Receptor Ligands,” Abstracts of Pap

Affiliated with

Also associated with

Rating

Substituted acylanilides and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted acylanilides and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted acylanilides and methods of use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4297138